A patient receives a prescription for oxybutynin (Ditropan) for the treatment of overactive bladder. Which instruction should the nurse include in patient teaching to help prevent the adverse effects of therapy?

Oxybutynin (Ditropan) is an anticholinergic (antimuscarinic) medication used to treat overactive bladder by relaxing the detrusor muscle. Its anticholinergic adverse effects include dry mouth, constipation, urinary retention, blurred vision, and cognitive effects. A critical safety teaching point is to avoid combining oxybutynin with other anticholinergic medications, such as diphenhydramine (Benadryl), which is itself a potent anticholinergic antihistamine. Taking both concurrently produces additive anticholinergic effects, significantly increasing the risk of adverse reactions including severe dry mouth, urinary retention, constipation, confusion, and heat intolerance. Patients must obtain provider approval before using any antihistamine while on oxybutynin. Emptying the bladder every three hours is a behavioral strategy for bladder training, not specifically related to preventing adverse drug effects. Oxybutynin causes decreased salivation, not increased salivation, so advising patients to drink less would be incorrect and dangerous. Oxybutynin causes constipation, not diarrhea, so an antidiarrheal such as diphenoxylate and atropine is irrelevant and adding atropine would further increase anticholinergic burden. Therefore, avoiding antihistamines without provider approval is the most important teaching to prevent compounded anticholinergic toxicity.